

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List; Proposed Additions

AGENCY: Committee for Purchase From People Who Are Blind or Severely Disabled.

ACTION: Proposed additions to procurement list.

SUMMARY: The Committee has received a proposal to add to the Procurement List services to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities.

COMMENTS MUST BE RECEIVED ON OR BEFORE: February 2, 2000.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Crystal Gateway 3, Suite 310, 1215 Jefferson Davis Highway, Arlington, Virginia 22202-4302.

FOR FURTHER INFORMATION CONTACT: Beverly Milkman (703) 603-7740.

SUPPLEMENTARY INFORMATION: This notice is published pursuant to 41 U.S.C. 47(a)(2) and 41 CFR 51-2.3. Its purpose is to provide interested persons an opportunity to submit comments on the possible impact of the proposed actions.

If the Committee approves the proposed additions, all entities of the Federal Government (except as otherwise indicated) will be required to procure the services listed below from nonprofit agencies employing persons who are blind or have other severe disabilities. I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the services to the Government.

2. The action will result in authorizing small entities to furnish the services to the Government.

3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46-48c) in connection with the services proposed for addition to the Procurement List. Comments on this certification are invited. Commenters should identify the statement(s) underlying the certification on which they are providing additional information.

The following services have been proposed for addition to Procurement

List for production by the nonprofit agencies listed:

Operation of Individual Equipment Element Store and HAZMART, Dover Air Force Base, Delaware

NPA: Blind Industries & Services of Maryland, Baltimore, Maryland
Provision of Customized Recognition and Award Program (50% of the total Government Requirement)

NPA: The Lighthouse for the Blind, Inc., Seattle, Washington

Beverly L. Milkman,

Executive Director.

[FR Doc. 99-34049 Filed 12-30-99; 8:45 am]

BILLING CODE 6353-01-P

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-853]

Notice of Preliminary Determination of Sales at Less Than Fair Value: Bulk Aspirin From the People's Republic of China

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

EFFECTIVE DATE: January 3, 2000.

FOR FURTHER INFORMATION CONTACT:

Blanche Ziv, Rosa Jeong or Ryan Langan, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, N.W., Washington, D.C. 20230; telephone: (202) 482-4207, (202) 482-3853, and (202) 482-1279, respectively.

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended ("the Act"), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department of Commerce ("Department") regulations are to 19 CFR Part 351 (April 1, 1998).

Preliminary Determination

We preliminarily determine that bulk aspirin ("aspirin") from the People's Republic of China ("PRC") is being, or is likely to be, sold in the United States at less than fair value ("LTFV"), as provided in section 733 of the Act. The estimated margins of sales at LTFV are shown in the "Suspension of Liquidation" section of this notice.

Case History

Since the initiation of this investigation on June 23, 1999 (64 FR

33463) ("*Notice of Initiation*"), the following events have occurred:

On June 15, 1999, we received an entry of appearance by counsel on behalf of Jilin Pharmaceutical Co., Ltd. ("Jilin"), a producer/exporter of the subject merchandise. On June 16, 1999, we received an entry of appearance by counsel on behalf of Shandong Xinhua Pharmaceutical Factory ("Shandong"), a producer/exporter of the subject merchandise.

On July 19, 1999, the United States International Trade Commission ("ITC") notified the Department of its affirmative preliminary injury determination in this case.

On July 26, 1999, the Department issued an antidumping questionnaire to the Ministry of Foreign Trade and Economic Cooperation ("MOFTEC"), the Embassy of the PRC, and the China Chamber of Commerce for Medicine and Health with instructions to forward the questionnaire to all producers/exporters of the subject merchandise. Also on July 26, 1999, the Department issued the antidumping questionnaire to Jilin and Shandong.

On September 3, 1999, the Department invited interested parties to provide publicly available information for valuing the factors of production and to comment on the surrogate country selection. We received responses on October 4, 1999, and additional comments on October 8 and 12, 1999.

On August 24 and 30, and September 3 and 7, 1999, the Department received questionnaire responses from Jilin and Shandong. We issued supplemental questionnaires on September 10, 1999, to which we received responses on October 4, 1999.

On October 8, 1999, pursuant to section 733(c)(1)(A) of the Act, Rhodia, Inc., the petitioner, made a timely request to postpone the issuance of the preliminary determination in this investigation. We granted this request and, on October 21, 1999, we postponed the preliminary determination until no later than December 21, 1999 (*See* 64 FR 56738).

On December 1, 1999, the petitioner submitted additional surrogate value information and preliminary determination comments. On December 6, 1999, Jilin filed corrections to its reported factor data. In addition, between December 6 and 16, 1999, Jilin filed several submissions objecting to the petitioner's submission of new surrogate value information. Shandong provided clarifications to its reported factor data on December 6, 1999.